Challenges in Preventing and Treating Hemolytic Complications Associated with Red Blood Cell Transfusion

Overview

Journal Transfus Clin Biol

Specialty Hematology

Date 2019 Apr 14

PMID 30979566

Citations 9

Authors

Satheesh Chonat

Connie M Arthur

Patricia E Zerra

Cheryl L Maier

Ryan P Jajosky

Marianne E M Yee

Maureen J Miller

Cassandra D Josephson

John D Roback

Ross Fasano

Sean R Stowell

Affiliations

Soon will be listed here.

Abstract

Red blood cell (RBC) transfusion support represents a critical component of sickle cell disease (SCD) management. However, as with any therapeutic intervention, RBC transfusion is not without risk. Repeat exposure to allogeneic RBCs can result in the development of RBC alloantibodies that can make it difficult to find compatible RBCs for future transfusions and can directly increase the risk of developing acute or delayed hemolytic transfusion reactions, which can be further complicated by hyperhemolysis. Several prophylactic and treatment strategies have been employed in an effort to reduce or prevent hemolytic transfusion reactions. However, conflicting data exist regarding the efficacy of many of these approaches. We will explore the challenges associated with predicting, preventing and treating different types of hemolytic transfusion reactions in patients with SCD in addition to describing future strategies that may aid in the management of the complex transfusion requirements of SCD patients.

Citing Articles

Harnessing the potential of red blood cells in immunotherapy.

Jajosky R, Zerra P, Chonat S, Stowell S, Arthur C Hum Immunol. 2024; 85(6):111084.

PMID: 39255557 PMC: 11808826. DOI: 10.1016/j.humimm.2024.111084.

ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies.

Jajosky R, Wu S, Zheng L, Jajosky A, Jajosky P, Josephson C iScience. 2023; 26(1):105798.

PMID: 36691627 PMC: 9860303. DOI: 10.1016/j.isci.2022.105798.

Prior immunization against an intracellular antigen enhances subsequent red blood cell alloimmunization in mice.

Jajosky R, Patel S, Wu S, Patel K, Covington M, Vallecillo-Zuniga M Blood. 2023; 141(21):2642-2653.

PMID: 36638335 PMC: 10356576. DOI: 10.1182/blood.2022016588.

Adverse events of red blood cell transfusions in patients with sickle cell disease.

Rollins M, Chou S Transfus Apher Sci. 2022; 61(5):103557.

PMID: 36064527 PMC: 10149091. DOI: 10.1016/j.transci.2022.103557.

How to avoid the problem of erythrocyte alloimmunization in sickle cell disease.

Pirenne F, Floch A, Habibi A Hematology Am Soc Hematol Educ Program. 2021; 2021(1):689-695.

PMID: 34889373 PMC: 8877235. DOI: 10.1182/hematology.2021000306.

References

Maier C, Mener A, Patel S, Jajosky R, Bennett A, Arthur C . Antibody-mediated immune suppression by antigen modulation is antigen-specific. Blood Adv. 2018; 2(21):2986-3000. PMC: 6234375. DOI: 10.1182/bloodadvances.2018018408. View

Lane W, Westhoff C, Gleadall N, Aguad M, Smeland-Wagman R, Vege S . Automated typing of red blood cell and platelet antigens: a whole-genome sequencing study. Lancet Haematol. 2018; 5(6):e241-e251. PMC: 6438177. DOI: 10.1016/S2352-3026(18)30053-X. View

Singhal D, Kutyna M, Chhetri R, Wee L, Hague S, Nath L . Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. Haematologica. 2017; 102(12):2021-2029. PMC: 5709101. DOI: 10.3324/haematol.2017.175752. View

Dean C, Maier C, Roback J, Stowell S . Multiple hemolytic transfusion reactions misinterpreted as severe vaso-occlusive crisis in a patient with sickle cell disease. Transfusion. 2018; 59(2):448-453. DOI: 10.1111/trf.15010. View

Klapper E, Zhang Y, Figueroa P, Ness P, Stubbs J, Abumuhor I . Toward extended phenotype matching: a new operational paradigm for the transfusion service. Transfusion. 2009; 50(3):536-46. DOI: 10.1111/j.1537-2995.2009.02462.x. View

Gardner K, Hoppe C, Mijovic A, Thein S . How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease. Br J Haematol. 2015; 170(6):745-56. DOI: 10.1111/bjh.13494. View

Schanfield M, Stevens J, Bauman D . The detection of clinically significant erythrocyte alloantibodies using a human mononuclear phagocyte assay. Transfusion. 1981; 21(5):571-6. DOI: 10.1046/j.1537-2995.1981.21582040822.x. View

Liepkalns J, Cadwell C, Stowell S, Hod E, Spitalnik S, Zimring J . Resistance of a subset of red blood cells to clearance by antibodies in a mouse model of incompatible transfusion. Transfusion. 2012; 53(6):1319-27. DOI: 10.1111/j.1537-2995.2012.03910.x. View

Mener A, Patel S, Arthur C, Chonat S, Wieland A, Santhanakrishnan M . Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses. JCI Insight. 2018; 3(22). PMC: 6302935. DOI: 10.1172/jci.insight.121631. View

10.

Vichinsky E, Luban N, Wright E, Olivieri N, Driscoll C, Pegelow C . Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion. 2001; 41(9):1086-92. DOI: 10.1046/j.1537-2995.2001.41091086.x. View

11.

Chonat S, Quarmyne M, Bennett C, Dean C, Joiner C, Fasano R . Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease. Haematologica. 2018; 103(10):e483-e485. PMC: 6165824. DOI: 10.3324/haematol.2018.194670. View

12.

Vidler J, Gardner K, Amenyah K, Mijovic A, Thein S . Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience. Br J Haematol. 2015; 169(5):746-53. DOI: 10.1111/bjh.13339. View

13.

Yazdanbakhsh K, Ware R, Noizat-Pirenne F . Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012; 120(3):528-37. PMC: 3401213. DOI: 10.1182/blood-2011-11-327361. View

14.

Merle N, Grunenwald A, Rajaratnam H, Gnemmi V, Frimat M, Figueres M . Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. JCI Insight. 2018; 3(12). PMC: 6124427. DOI: 10.1172/jci.insight.96910. View

15.

Chou S, Liem R, Thompson A . Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol. 2012; 159(4):394-404. DOI: 10.1111/bjh.12061. View

16.

Fasano R, Booth G, Miles M, Du L, Koyama T, Meier E . Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease. Br J Haematol. 2014; 168(2):291-300. DOI: 10.1111/bjh.13123. View

17.

Chou S, Jackson T, Vege S, Smith-Whitley K, Friedman D, Westhoff C . High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013; 122(6):1062-71. DOI: 10.1182/blood-2013-03-490623. View

18.

Fasano R, Sullivan H, Bray R, Gebel H, Meyer E, Winkler A . Genotyping Applications for Transplantation and Transfusion Management: The Emory Experience. Arch Pathol Lab Med. 2017; 141(3):329-340. PMC: 5873318. DOI: 10.5858/arpa.2016-0277-SA. View

19.

Pirenne F, Yazdanbakhsh K . How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. Blood. 2018; 131(25):2773-2781. PMC: 6014354. DOI: 10.1182/blood-2018-02-785964. View

20.

Hosoba S, Jaye D, Cohen C, Roback J, Waller E . Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature. Transfusion. 2014; 55(2):259-64. PMC: 4342762. DOI: 10.1111/trf.12815. View